Alternative splicing in disease and therapy

Nature Biotechnology

Volumn 22, Issue 5, 2004, Pages 535-546

  Garcia Blanco, Mariano A ^a   Baraniak, Andrew P ^a   Lasda, Erika L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MUTAGENESIS; PATIENT TREATMENT; PROTEINS;

CRYPTIC EXONS; CYSTIC FIBROSIS; PROTEOME DIVERSITY;

BIOTECHNOLOGY;

ACLARUBICIN; ANTISENSE OLIGONUCLEOTIDE; BUTYRIC ACID; CASPASE 9; CIS ACTING ELEMENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA TOPOISOMERASE INHIBITOR; HISTONE DEACETYLASE; IBUPROFEN; INTERFERON; INTERLEUKIN 5 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; PARACETAMOL; PROTEIN BCL X; PROTEOME; TRANS ACTING FACTOR; VALPROIC ACID;

ALTERNATIVE RNA SPLICING; ANALGESIA; CYSTIC FIBROSIS; EXON; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

ALTERNATIVE SPLICING; BASE SEQUENCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; RNA; THERAPEUTICS;

EID: 2342450548     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt964     Document Type: Review

References (186)

1. Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
2. Lander, E.S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
3. Garcia-Blanco, M.A., Ghosh, S. & Lindsey-Boltz, L.A. The phosphoryl transfer reactions in pre-messenger RNA splicing. in RNA. (eds. Soll, D., Nishimura, S. & Moore, P.B.) 109-123 (Pergamon, Amsterdam, 2001).
4. Jurica, M.S. & Moore, M.J. Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell 12, 5-14 (2003).
5. Nilsen, T.W. The spliceosome: the most complex macromolecular machine in the cell? Bioessays 25, 1147-1149 (2003).
6. Modrek, B. & Lee, C.J. Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat. Genet. 34, 177-180 (2003).
7. Johnson, J.M. et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302, 2141-2144 (2003).
8. Sorek, R., Shamir, R. & Ast, G. How prevalent is functional alternative splicing in the human genome? Trends Genet. 20, 68-71 (2004).
9. Resch, A. et al. Assessing the impact of alternative splicing on domain interactions in the human proteome. J. Proteome Res. 3, 76-83 (2004).
10. Caceres, J.F. & Kornblihtt, A.R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18, 186-193 (2002).
11. Cartegni, L., Chew, S.L. & Kralner, A.R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285-298 (2002).
12. Faustino, N.A. & Cooper, T.A. Pre-mRNA splicing and human disease. Genes Dev. 17, 419-437 (2003).
13. Musunuru, K. Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc. Med. 13, 188-195 (2003).
14. Roca, X., Sachidanandam, R. & Krainer, A.R. Intrinsic differences between authentic and cryptic 5′ splice sites. Nucleic Acids Res. 31, 6321-6333 (2003).
15. Goldstrohm, A.C., Greenleaf, A.L. & Garcia-Blanco, M.A. Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing. Gene 277, 31-47 (2001).
16. Burge, C.B., Padgett, R.A. & Sharp, P.A. Evolutionary fates and origins of U12-type introns. Mol. Cell. 2, 773-785 (1998).
17. Lim, L.P. & Burge, C.B. A computational analysis of sequence features involved in recognition of short introns. Proc. Natl. Acad. Sci. USA 98, 11193-11198 (2001).
18. Patel, A.A. & Steitz, J.A. Splicing double: insights from the second spliceosome. Nat. Rev. Mol. Cell. Biol. 4, 960-970 (2003).
19. Fairbrother, W.G., Yeh, R.F., Sharp, P.A. & Burge, C.B. Predictive identification of exonic splicing enhancers in human genes. Science 297, 1007-1013 (2002).
20. Cartegni, L., Wang, J., Zhu, Z., Zhang, M.Q. & Krainer, A.R. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31, 3568-3571 (2003).
21. Fairbrother, W.G. & Chasin, L.A. Human genomic sequences that inhibit splicing. Mol. Cell. Biol. 20, 6816-6825 (2000).
22. Zhang, X.H., Heller, K.A., Hefter, I., Leslie, C.S. & Chasin, L.A. Sequence information for the splicing of human pre-mRNA identified by support vector machine classification. Genome Res. 13, 2637-2650 (2003).
23. Berget, S.M. Exon recognition in vertebrate splicing. J. Biol. Chem. 270, 2411-2414 (1995).
24. Labrador, M. & Corces, V.G. Extensive exon reshuffling over evolutionary time coupled to trans-splicing in Drosophila. Genome Res. 13, 2220-2228 (2003).
25. Graveley, B.R. Sorting out the complexity of SR protein functions. RNA 6, 1197-1211 (2000).
26. Del Gatto-Konczak, F., Olive, M., Gesnel, M.C. & Breathnach, R. hnRNP A1 recruited to an exon in vivo can function as an exon splicing silencer. Mol. Cell Biol. 19, 251-260 (1999).
27. Zhu, J., Mayeda, A. & Krainer, A.R. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol. Cell 13, 1351-1361 (2001).
28. Caceres, J.F., Stamm, S., Helfman, D.M. & Krainer, A.R. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science 265, 1706-1709 (1994).
29. Del Gatto-Konczak, F. et al. The RNA-binding protein TIA-I is a novel mammalian splicing regulator acting through intron sequences adjacent to a 5′ splice site. Mol. Cell Biol. 20, 6287-6299 (2000).
30. Del Gatto, F., Plet, A., Gesnel, M.C., Fort, C. & Breathnach, R. Multiple interdependent sequence elements control splicing of a fibroblast growth factor receptor 2 alternative exon. Mol. Cell Biol. 17, 5106-5116 (1997).
31. Valcarcel, J., Singh, R., Zamore, P.D. & Green, M.R. The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature 362, 171-175 (1993).
32. Horabin, J.L. & Schedl, P. Sex-lethal autoregulation requires multiple cis-acting elements upstream and downstream of the male exon and appears to depend largely on controlling the use of the male exon 5′ splice site. Mol. Cell Biol. 13, 7734-7746 (1993).
33. Chou, M.Y., Underwood, J.G., Nikolic, J., Luu, M.H. & Black, D.L. Multisite RNA binding and release of polypyrimidine tract binding protein during the regulation of c-src neural-specific splicing. Mol. Cell 5, 949-957 (2000).
34. Wagner, F.J. & Garcia-Blanco, M.A. Polypyrimidine tract binding protein antagonizes exon definition. Mol. Cell Biol. 21, 3281-3288 (2001).
35. Charlet, B.N. et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10, 45-53 (2002).
36. Carstens, R.P., McKeehan, W.L. & Garcia-Blanco, M.A. An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing. Mol. Cell Biol. 18, 2205-2217 (1998).
37. Baraniak, A.P., Lasda, E.L., Wagner, E.J. & Garcia-Blanco, M.A. A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol. Cell Biol. 23, 9327-9337 (2003).
38. Lewis, B.P., Green, R.E. & Brenner, S.E. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc. Natl. Acad. Sci. USA 100, 189-192 (2003).
39. Maquat, L.E. Nonsense-mediated mRNA decay. Curr. Biol. 12, R196-197 (2002).
40. Jones, R.B. et al. The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs. J. Biol. Chem. 276, 4158-4167 (2001).
41. Wagner, E.J. et al. Quantification of alternatively spliced FGFR2 RNAs using the RNA invasive cleavage assay. RNA 9, 1552-1561 (2003).
42. Wollerton, M.C., Gooding, C., Wagner, E.J., Garcia-Blanco, M.A. & Smith, C.W. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol. Cell 13, 91-100 (2004).
43. Le Guiner, C. et al. TIA-1 and TIAR activate splicing of alternative exons with weak 5′ splice sites followed by a U-rich stretch on their own pre-mRNAs. J. Biol. Chem. 276, 40638-40646 (2001).
44. Stenson, P.D. et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577-581 (2003).
45. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S. & McKeehan, W.L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell Biol. 13, 4513-4522 (1993).
46. Busslinger, M., Moschonas, N. & Flavell, R.A. Beta+ thalassemia: aberrant splicing results from a single point mutation in an intron. Cell 27, 289-298 (1981).
47. Spritz, R.A. et al. Base substitution in an intervening sequence of a beta+-thalassemic human globin gene. Proc. Natl. Acad. Sci. USA 78, 2455-2459 (1981).
48. Helmken, C. et al. Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum. Genet. 114, 11-21 (2003).
49. Lorson, C.L., Hahnen, E., Androphy, E.J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 96, 6307-6311 (1999).
50. Kashima, T. & Manley, J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34, 460-463 (2003).
51. Singh, N.N., Androphy, E.J. & Singh, R.N. An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem. Biophys. Res. Commun. 315, 381-388 (2004).
52. Mine, M. et al. Splicing error in E1alpha pyruvate dehydrogenase mRNA caused by novel intronic mutation responsible for lactic acidosis and mental retardation. J. Biol. Chem. 278, 11768-11772 (2003).
53. Maquat, L.E. et al. Processing of human beta-globin mRNA precursor to mRNA is defective in three patients with beta+-thalassemia. Proc. Natl. Acad. Sci. USA 77, 4287-4291 (1980).
54. Rees, D.J., Rizza, C.R. & Brownlee, G.G. Haemophilia B caused by a point mutation in a donor splice junction of the human factor IX gene. Nature 316, 643-645 (1985).
55. Ryther, R.C. et al. Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. Hum. Genet. 113, 140-148 (2003).
56. Millar, D.S. et al. Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Hum. Mutat. 21, 424-440 (2003).
57. Kanadia, R.N. et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978-1980 (2003).
58. Gunthert, U. et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991).
59. Daoud, R. et al. Ischemia induces a translocation of the splicing factor tra2-beta 1 and changes alternative splicing patterns in the brain. J. Neurosci. 22, 5889-5899 (2002).
60. Boucher, R.C. in Harrison's Principles of Internal Medicine, edn. 15 (ed. Braunwald, E. et al.) 1487-1491 (McGraw-Hill, New York, 2001).
61. Noone, P.G. & Knowles, M.R. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir. Res. 2, 328-332 (2001).
62. Rowntree, R.K. & Harris, A. The phenotypic consequences at CFTR mutations. Ann. Hum. Genet. 67, 471-485 (2003).
63. Chu, C.S., Trapnell, B.C., Curristin, S., Cutting, G.R. & Crystal, R.G. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat. Genet. 3, 151-156 (1993).
64. Teng, H. et al. Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum. Mol. Genet. 6, 85-90 (1997).
65. Mak, V., Jarvi, K.A., Zielenski, J., Durie, P. & Tsui, L.C. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum. Mol. Genet. 6, 2099-2107 (1997).
66. Larriba, S. et al. Testicular CFTR splice variants in patients with congenital absence of the vas deferens. Hum. Mol. Genet. 7, 1739-1743 (1998).
67. Hefferon, T.W., Broackes-Carter, F.C., Harris, A. & Cutting, G.R. Atypical 5′ splice sites cause CFTR exon 9 to be vulnerable to skipping. Am. J. Hum. Genet. 71, 294-303 (2002).
68. Costes, B. et al. Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens. Eur. J. Hum. Genet. 3, 285-293 (1995).
69. Cuppens, H. et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J. Clin. Invest. 101, 487-496 (1998).
70. Niksic, M., Romano, M., Buratti, E., Pagani, F. & Baralle, F.E. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum. Mol. Genet. 8, 2339-2349 (1999).
71. Zuccato, E., Buratti, E., Stuani, C., Baralle, F.E. & Pagani, F. An intronic polypyrimidine-rich element downstream of the donor site modulates CFTR exon 9 alternative splicing. J. Biol. Chem., published online 13 February 2004 (PMID: 14966131).
72. Pagani, F., Buratti, E., Stuani, C. & Baralle, F.E. Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9. J. Biol. Chem. 278, 26580-26588 (2003).
73. Ou, S.H., Wu, F., Harrich, D., Garcia-Martinez, L.F. & Gaynor, R.B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69, 3584-3596 (1995).
74. Buratti, E. & Baralle, F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 276, 36337-36343 (2001).
75. Buratti, E. et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 20, 1774-1784 (2001).
76. Nissim-Rafinia, M., Chiba-Falek, O., Sharon, G., Boss, A. & Kerem, B. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum. Mol. Genet. 9, 1771-1778 (2000).
77. Pagani, F. et al. Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element. J. Biol. Chem. 275, 21041-21047 (2003).
78. Chiba-Falek, O. et al. The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C→T mutation. Genomics 53, 276-283 (1998).
79. Aznarez, I., Chan, E.M., Zielenski, J., Blencowe, B.J. & Tsui, L.C. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene. Hum. Mol. Genet. 12, 2031-2040 (2003).
80. Nissim-Rafinia, M. & Kerem, B. Splicing regulation as a potential genetic modifier. Trends Genet. 18, 123-127 (2002).
81. Buchner, D.A., Trudeau, M. & Meisler, M.H. SCNM1, a putative RNA splicing factor that modifies disease severity in mice. Science 301, 967-969 (2003).
82. Van Deerlin, V.M., Gill, L.H., Farmer, J.M., Trojanowski, J.Q. & Lee, V.M. Familial frontotemporal dementia: from gene discovery to clinical molecular diagnostics. Clin. Chem. 49, 1717-1725 (2003).
83. Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E. & Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA 85, 4051-4055 (1988).
84. Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J. & Crowther, R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393-399 (1989).
85. Geodert, M., Spillantini, M.G., Jakes, R., Rutherford, D. & Crowther, R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526 (1989).
86. Andreadis, A., Brown, W.M. & Kosik, K.S. Structure and novel exons of the human tau gene. Biochemistry 31, 10626-10633 (1992).
87. Lee, G., Neve, R.L. & Kosik, K.S. The microtubule binding domain of tau protein. Neuron 2, 1615-1624 (1989).
88. Goedert, M. & Jakes, R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 9, 4225-4230 (1990).
89. Hutton, M. et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
90. Hong, M. et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914-1917 (1998).
91. Spillantini, M.G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95, 7737-7741 (1998).
92. Goedert, M., Ghetti, B. & Spillantini, M.G. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann. NY Acad. Sci. 920, 74-83 (2000).
93. Lynch, T. et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 44, 1878-1884 (1994).
94. Kowalska, A. et al. A novel mutation at position +11 in the intron following exon 10 of the tau gene in FTDP-17. J. Appl. Genet. 43, 535-543 (2002).
95. Grover, A., DeTure, M., Yen, S.H. & Hutton, M. Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci. Lett. 323, 33-36 (2002).
96. Tolnay, M. et al. A new case of frontotemporal dementia and parkinsonism resulting from an intron 10 +3-splice site mutation in the tau gene: clinical and pathological features. Neuropathol. Appl. Neurobiol. 26, 368-378 (2000).
97. Stanford, P.M. et al. Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain 126, 814-826 (2003).
98. D'Souza, I. et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA 96, 5598-5603 (1999).
99. Gao, Q.S. et al. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. J. Neurochem. 74, 490-500 (2000).
100. Jiang, Z., Cate, J., Kwon, J.M., Goate, A.M. & Wu, J.Y. Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. Mol. Cell. Biol. 20, 4036-4048 (2000).
101. Varani, L. et al. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc. Natl. Acad. Sci. USA 96, 8229-8234 (1999).
102. Clark, L.N. et al. Pathogenic implications of mutations in the tau gene in pallido-pontonigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA 95, 13103-13107 (1998).
103. Jiang, Z. et al. Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta. J. Biol. Chem. 278, 18997-19007 (2003).
104. Grover, A. et al. 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J. Biol. Chem. 274, 15134-15143 (1999).
105. Bracco, L. & Kearsey, J. The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol. 21, 346-353 (2003).
106. Simmons, D.L. Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res. 110, 265-268 (2003).
107. Bingham, C.O. 3rd Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve. Clin. J. Med. (suppl. 1) 69, S15-12 (2002).
108. Chandrasekharan, N.V. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99, 13926-13931 (2002).
109. Shaftel, S.S., Olschowka, J.A., Hurley, S.D., Moore, A.H. & O'Banion, M.K. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res. Mol. Brain Res. 119, 213-215 (2003).
110. Flower, R.J. & Vane, J.R. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240, 410-411 (1972).
111. Heider, K.H., Kuthan, H., Stehle, G. & Munzert, G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol. Immunother. (2004).
112. Baron-Delage, S., Abadie, A., Echaniz-Laguna, A., Melki, J. & Beretta, L. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol. Med. 6, 957-968 (2000).
113. Brichta, L. et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12, 2481-2489 (2003).
114. Chang, J.G. et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA 98, 9808-9813 (2001).
115. Kramer, O.H. et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22, 3411-3420 (2003).
116. Atweh, G.F. & Schechter, A.N. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr. Opin. Hematol. 8, 123-130 (2001).
117. Isoherranen, N., Yagen, B. & Bialer, M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol. 16, 203-211 (2003).
118. Larsen, A.K., Escargueil, A.E. & Skladanowski, A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 99, 167-181 (2003).
119. Andreassi, C. et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. 10, 2841-2849 (2001).
120. Muraki, M. et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem., published on line 8 March 2004 (PMID: 15010457).
121. Chalfant, C.E. et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J. Biol. Chem. 277, 12587-12595 (2002).
122. Auboeuf, D. et al. Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes. Proc. Natl. Acad. Sci. USA 101, 2270-2274 (2004).
123. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133, 467-474 (2002).
124. Crooke, S.T. Progress in antisense technology. Annu. Rev. Med. 55, 61-95 (2004).
125. Sazani, P. & Kole, R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest. 112, 481-486 (2003).
126. Zamecnik, P.C. & Stephenson, M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-284 (1978).
127. Stephenson, M.L. & Zamecnik, P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 75, 285-288 (1978).
128. Lacerra, G. et al. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA 97, 9591-9596 (2000).
129. Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 90, 8673-8677 (1993).
130. Vacek, M.M. et al. High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood 101, 104-111 (2003).
131. Gorman, L., Suter, D., Emerick, V., Schumperli, D. & Kole, R. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc. Natl. Acad. Sci. USA 95, 4929-4934 (1998).
132. De Angelis, F.G. et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc. Natl. Acad. Sci. USA 99, 9456-9461 (2002).
133. Friedman, K.J. et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193-36199 (1999).
134. Dunckley, M.G., Manoharan, M., Villiet, P., Eperon, I.C. & Dickson, G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7, 1083-1090 (1998).
135. Wilton, S.D. et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul. Disord. 9, 330-338 (1999).
136. Taylor, J.K., Zhang, Q.Q., Wyatt, J.R. & Dean, N.M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097-1100 (1999).
137. Karras, J.G., Maier, M.A., Lu, T., Watt, A. & Manoharan, M. Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain. Biochemistry 40, 7853-7859 (2001).
138. Kalbfuss, B., Mabon, S.A. & Misteli, T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276, 42986-42993 (2001).
139. Sazani, P. et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233 (2002).
140. Mann, C.J. et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA 98, 42-47 (2001).
141. Lu, Q.L. et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-1014 (2003).
142. Villemaire, J., Dion, I., Elela, S.A. & Chabot, B. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J. Biol. Chem. 278, 50331-50339 (2003).
143. Skordis, L.A., Dunckley, M.G., Yue, B., Eperon, I.C. & Muntoni, F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. USA 100, 4114-4119 (2003).
144. Cartegni, L. & Krainer, A.R. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol. 10, 120-125 (2003).
145. Graveley, B.R. & Maniatis, T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol. Cell 1, 765-771 (1998).
146. Graveley, B.R., Hertel, K.J. & Maniatis, T. A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J. 17, 6747-6756 (1998).
147. Buratti, E., Baralle, F.E. & Pagani, F. Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better? Trends Mol. Med. 9, 229-232; discussion 233-224 (2003).
148. Eperon, I.C. & Muntoni, F. Response to Buratti et al.: Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better? Trends Mol. Med. 9, 233-234 (2003).
149. Khoo, B., Akker, S.A. & Chew, S.L. Putting some spine into alternative splicing. Trends Biotechnol. 21, 328-330 (2003).
150. Liu, Q. & Dreyfuss, G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15, 3555-3565 (1996).
151. Coovert, D.D. et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205-1214 (1997).
152. Mercatante, D.R., Sazani, P. & Kole, R. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr. Cancer Drug Targets 1, 211-230 (2001).
153. Hommel, J.D., Sears, R.M., Georgescu, D., Simmons, D.L. & DiLeone, R.J. Local gene knockdown in the brain using viral-mediated RNA interference. Nat. Med. 9, 1539-1544 (2003).
154. Dykxhoorn, D.M., Novina, C.D. & Sharp, P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4, 457-467 (2003).
155. Wall, N.R. & Shi, Y. Small RNA: can RNA interference be exploited for therapy? Lancet 362, 1401-1403 (2003).
156. Celotto, A.M. & Graveley, B.R. Exon-specific RNAi: a tool for dissecting the functional relevance of alternative splicing. RNA 8, 718-724 (2002).
157. Garcia-Blanco, M.A. Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J. Clin. Invest. 112, 474-480 (2003).
158. Sullenger, B.A. & Gilboa, E. Emerging clinical applications of RNA. Nature 418, 252-258 (2002).
159. Puttaraju, M., Jamison, S.F., Mansfield, S.G., Garcia-Blanco, M.A. & Mitchell, L.G. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat. Biotechnol. 17, 246-252 (1999).
160. Liu, X. et al. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat. Biotechnol. 20, 47-52 (2002).
161. Chao, H. et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med. 9, 1015-1019 (2003).
162. Sullenger, B.A. & Cech, T.R. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 371, 619-622 (1994).
163. Watanabe, T. & Sullenger, B.A. RNA repair: a novel approach to gene therapy. Adv. Drug Deliv. Rev. 44, 109-118 (2000).
164. Rogers, C.S., Vanoye, C.G., Sullenger, B.A. & George, A.L. Jr. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J. Clin. Invest. 110, 1783-1789 (2002).
165. Deidda, G., Rossi, N. & Tocchini-Valentini, G.P. An archaeal endoribonuclease catalyzes cis- and trans-nonspliceosomal splicing in mouse cells. Nat. Biotechnol. 21, 1499-1504 (2003).
166. Roberts, R. et al. Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. Proc. Natl. Acad. Sci. USA 94, 13221-13226 (1997).
167. Lu, X., Timchenko, N.A. & Timchenko, L.T. Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded in myotonic dystrophy. Hum. Mol. Genet. 8, 53-60 (1999).
168. Yang, L., Embree, L.J. & Hickstein, D.D. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol. Cell Biol. 20, 3345-3354 (2000).
169. Crozat, A., Aman, P., Mandahl, N. & Ron, O. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363, 640-644 (1993).
170. Ichikawa, H., Shimizu, K., Hayashi, Y. & Ohki, M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54, 2865-2868 (1994).
171. Lovestone, S. et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086 (1994).
172. Hernandez, F. et al. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J. Biol. Chem. 279, 3801-3806 (2004).
173. Manabe, T. et al. Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease. Cell Death Differ. 10, 698-708 (2003).
174. Miller, J.W. et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19, 4439-4448 (2000).
175. Buckanovich, R.J., Posner, J.B. & Darnell, R.B. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 11, 657-672 (1993).
176. Jensen, K.B. et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron 25, 359-371 (2000).
177. Chakarova, C.F. et al. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 87-92 (2002).
178. Vithana, E.N. et al. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol. Cell 8, 375-381 (2001).
179. McKie, A.B. et al. Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). Hum. Mol. Genet. 10, 1555-1562 (2001).
180. Ma, K. et al. A Y chromosome gene family with RNA-binding protein homology: candidates for the azoospermia factor AZF controlling human spermatogenesis. Cell 75, 1287-1295 (1993).
181. Venables, J.P. et al. RBMY, a probable human spermatogenesis factor, and other hnRNP G proteins interact with Tra2beta and affect splicing. Hum. Mol. Genet. 9, 685-694 (2000).
182. Imai, H., Chan, E.K., Kiyosawa, K., Fu, X.D. & Tan, E.M. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J. Clin. Invest. 92, 2419-2426 (1993).
183. Clark, J. et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15, 2233-2239 (1997).
184. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165 (1995).
185. Fomenkov, A. et al. P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J. Biol. Chem. 278, 23906-23914 (2003).
186. Srivastava, S. et al. SMN2-deletion in childhood-onset spinal muscular atrophy. Am. J. Med. Genet. 101, 198-202 (2001).